Gwynn Douglas Long, MD

Professor of Medicine
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address gwynn.long@duke.edu

1. High dose therapy and autologous and allogeneic stem cell rescue for hematologic malignancies (especially multiple myeloma) and solid tumors.
2. Non-myeloablative allogeneic transplants for hematologic malignancies and solid tumors.
3. Supportive care for hematopoietic stem cell transplants.
4. Prevention and therapy of graft versus host disease.

Education and Training

  • Fellow in Medical Oncology, Medicine, Stanford University, 1987 - 1990
  • Medical Resident, Medicine, Vanderbilt University, 1983 - 1986
  • M.D., Wake Forest University, 1983
  • M.S., Wake Forest University, 1979

Publications

Tuchman, Sascha A., Wendi A. Bacon, Li-Wen Huang, Gwynn Long, David Rizzieri, Mitchell Horwitz, John P. Chute, et al. “Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma..” J Clin Apher 30, no. 3 (June 2015): 176–82. https://doi.org/10.1002/jca.21360.

PMID
25293363
Full Text

Long, Gwynn, Edmund K. Waller, Steven Gregurek, Guido Tricot, Susanne Marschner, and Jerry Bill. “Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients..” J Clin Apher 30, no. 1 (February 2015): 1–7. https://doi.org/10.1002/jca.21341.

PMID
24941931
Full Text

Tuchman, Sascha A., Amy Lane, Whitney E. Hornsby, Caroline Bishop, Samantha Thomas, James E. Herndon, Gwynn Long, Cristina Gasparetto, and Lee W. Jones. “Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study..” Clin Lymphoma Myeloma Leuk 15, no. 2 (February 2015): 103–9. https://doi.org/10.1016/j.clml.2014.09.002.

PMID
25445473
Full Text

Horwitz, Mitchell E., Nelson J. Chao, David A. Rizzieri, Gwynn D. Long, Keith M. Sullivan, Cristina Gasparetto, John P. Chute, et al. “Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment..” J Clin Invest 124, no. 7 (July 2014): 3121–28. https://doi.org/10.1172/JCI74556.

PMID
24911148
Full Text

Kanda, Junya, Gwynn D. Long, Cristina Gasparetto, Mitchell E. Horwitz, Keith M. Sullivan, John P. Chute, Ashley Morris, et al. “Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies..” Biol Blood Marrow Transplant 20, no. 2 (February 2014): 257–63. https://doi.org/10.1016/j.bbmt.2013.11.010.

PMID
24269380
Full Text

Kanda, J., L. Kaynar, Y. Kanda, V. K. Prasad, S. H. Parikh, L. Lan, T. Shen, et al. “Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment..” Bone Marrow Transplant 48, no. 7 (July 2013): 926–31. https://doi.org/10.1038/bmt.2012.279.

PMID
23334274
Full Text

Held, Lauren A., David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, and Cristina Gasparetto. “A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma..” Cancer Invest 31, no. 3 (March 2013): 172–76. https://doi.org/10.3109/07357907.2012.756109.

PMID
23406188
Full Text

Kanda, Junya, Lun-Wei Chiou, Paul Szabolcs, Gregory D. Sempowski, David A. Rizzieri, Gwynn D. Long, Keith M. Sullivan, et al. “Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation..” Biol Blood Marrow Transplant 18, no. 11 (November 2012): 1664-1676.e1. https://doi.org/10.1016/j.bbmt.2012.06.005.

PMID
22698485
Full Text

Spasojevic, Ivan, Ligia R. S. da Costa, Mitchell E. Horwitz, Gwynn D. Long, Keith M. Sullivan, John P. Chute, Cristina Gasparetto, Ashley Morris, Nelson J. Chao, and David A. Rizzieri. “Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry..” Cancer Invest 30, no. 9 (November 2012): 679–82. https://doi.org/10.3109/07357907.2012.726386.

PMID
23020519
Full Text

Jagasia, M. H., R. Abonour, G. D. Long, B. J. Bolwell, G. G. Laport, T. B. Shore, S. Durrant, et al. “Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial..” Bone Marrow Transplant 47, no. 10 (October 2012): 1350–55. https://doi.org/10.1038/bmt.2011.261.

PMID
22327131
Full Text

Pages